STOCK TITAN

OnKure Therapeutics (OKUR) awards 110,000 options to Chief Scientific Officer

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Hartley Dylan reported acquisition or exercise transactions in this Form 4 filing.

OnKure Therapeutics, Inc. reported that Chief Scientific Officer Dylan Hartley received a grant of 110,000 employee stock options to buy Class A Common Stock at $4.07 per share. These options expire on March 31, 2036 and function as equity-based compensation rather than an open-market share purchase.

According to the vesting terms, 1/48th of the options will vest on May 1, 2026 and then monthly thereafter, as long as Hartley continues as a service provider. After this grant, Hartley directly holds 110,000 options covering an equal number of Class A Common shares.

Positive

  • None.

Negative

  • None.
Insider Hartley Dylan
Role Chief Scientific Officer
Type Security Shares Price Value
Grant/Award Employee Stock Option (right to buy) 110,000 $0.00 --
Holdings After Transaction: Employee Stock Option (right to buy) — 110,000 shares (Direct)
Footnotes (1)
  1. [object Object]
Options granted 110,000 options Employee Stock Option grant to Chief Scientific Officer
Exercise price $4.07 per share Strike price for Class A Common Stock under the option
Underlying shares 110,000 shares Class A Common Stock underlying the employee stock options
Expiration date March 31, 2036 Option expiration for the 110,000 granted options
Post-grant option holdings 110,000 options Total derivative holdings following this grant
Initial vesting date May 1, 2026 First vesting date for 1/48th of the options
Vesting rate 1/48th monthly Monthly vesting schedule, contingent on continued service
Employee Stock Option financial
"security_title: "Employee Stock Option (right to buy)""
An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.
Class A Common Stock financial
"underlying_security_title: "Class A Common Stock""
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
exercise price financial
"conversion_or_exercise_price: "4.0700""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"1/48th of the shares subject to the option shall vest on May 1, 2026 and each month thereafter"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
derivative financial
""transaction_type": "derivative""
A derivative is a financial contract whose value depends on the price or performance of another asset or measure — for example a stock, index, interest rate, commodity, or currency. Investors use derivatives like insurance or leveraged bets to hedge risk, speculate, or gain exposure without owning the underlying asset; they can protect portfolios but also amplify losses and introduce counterparty and market risk.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hartley Dylan

(Last)(First)(Middle)
C/O ONKURE THERAPEUTICS, INC.
6707 WINCHESTER CIRCLE, SUITE 400

(Street)
BOULDER COLORADO 80301

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
OnKure Therapeutics, Inc. [ OKUR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Scientific Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (right to buy)$4.0704/01/2026A110,000 (1)03/31/2036Class A Common Stock110,000$0110,000D
Explanation of Responses:
1. 1/48th of the shares subject to the option shall vest on May 1, 2026 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
/s/ Rogan Nunn, by power of attorney04/03/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did OnKure Therapeutics (OKUR) report for Dylan Hartley?

OnKure reported that Chief Scientific Officer Dylan Hartley received a grant of 110,000 employee stock options. These options give him the right to buy Class A Common Stock at $4.07 per share as part of his equity-based compensation package.

What are the key terms of Dylan Hartley’s 110,000 OnKure stock options?

Hartley’s grant covers 110,000 employee stock options with an exercise price of $4.07 per share. The options relate to Class A Common Stock and expire on March 31, 2036, providing a long-dated incentive tied to the company’s future share performance.

How do Dylan Hartley’s OnKure (OKUR) stock options vest over time?

The options vest gradually, with 1/48th of the 110,000 options vesting on May 1, 2026. Additional 1/48th portions vest each month afterward, provided Hartley continues as a service provider, creating a four-year monthly vesting schedule linked to ongoing service.

Do Dylan Hartley’s OnKure options represent an open-market share purchase?

No, the Form 4 shows a grant of employee stock options classified as a derivative award, not an open-market share purchase. The transaction code “A” indicates a grant or award acquisition at $0.00 cost, with a $4.07 per share exercise price for future potential purchases.

How many OnKure shares are underlying Dylan Hartley’s new option grant?

The grant covers options for 110,000 underlying shares of OnKure’s Class A Common Stock. Following this transaction, the Form 4 shows Hartley directly holds 110,000 options, each tied to one share, aligning his potential future ownership with the option award size.

When do Dylan Hartley’s OnKure stock options expire if unexercised?

The options expire on March 31, 2036 if they are not exercised before that date. This long-term expiration gives Hartley a significant window to potentially exercise the 110,000 options at the $4.07 strike price, subject to vesting and continued service conditions.